15 december, van de Stolpe:
However, the setback with filgo also opens a new chapter for Galapagos. We were able to negotiate full commercial rights for filgo in Europe, a great improvement of the existing situation and an opportunity our commercial team could only have dreamt about.
We will now work closely with Gilead to move their people and expertise to Galapagos to ensure a successful continuation of the launch. Separately, both companies remain committed to our long-term collaboration to discover and develop new therapies for inflammatory diseases, fibrosis and beyond.
Hoe snel kan het gaan.
Infectie ziektes en fibrose: afgeschreven door Gilead.